Literature DB >> 14981342

Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior.

Kazuhiko Iwahashi1, Chikako Waga, Takahiro Takimoto.   

Abstract

The relationship between nicotine metabolism of CYP2A6 and the smoking behavior in a Japanese population was investigated. The CYP2A6 genotypes were determined by the PCR method. There was a significant difference in the frequency of the CYP2A6AST;4C allele, which is a whole deleted allele for the human CYP2A6 gene, between smokers and nonsmokers. The frequency of the CYP2A6AST;4C allele was higher in nonsmokers than in smokers, whereas the frequency of CYP2A6AST;1A/AST;1B heterozygotes with a higher activity of nicotine metabolism was lower. In this study it was suggested that the CYP2A6AST;4C allele may prevent the carrier from smoking and the CYP2A6AST;1A/AST;1B heterozygote may be at risk for developing smoking behavior. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981342     DOI: 10.1159/000076418

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  9 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

2.  Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole.

Authors:  Jeannine Chan; Tyler Oshiro; Sarah Thomas; Allyson Higa; Stephen Black; Aleksandar Todorovic; Fawzy Elbarbry; John P Harrelson
Journal:  Drug Metab Dispos       Date:  2016-02-05       Impact factor: 3.922

Review 3.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

4.  A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.

Authors:  Nael Al Koudsi; Jasjit S Ahluwalia; Shih-Ku Lin; Edward M Sellers; Rachel F Tyndale
Journal:  Pharmacogenomics J       Date:  2009-04-14       Impact factor: 3.550

5.  Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.

Authors:  J C Mwenifumbo; C N Lessov-Schlaggar; Q Zhou; R E Krasnow; G E Swan; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

Review 6.  Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.

Authors:  Riju Ray; Rachel F Tyndale; Caryn Lerman
Journal:  J Neurogenet       Date:  2009-01-23       Impact factor: 1.250

7.  Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men.

Authors:  Wei-Chih Ou; Yi-Chin Huang; Chih-Ling Huang; Min-Hsuan Lin; Yi-Chun Chen; Yi-Ju Chen; Chen-Nu Liu; Mei-Chih Chen; Ching-Shan Huang; Pei-Lain Chen
Journal:  Behav Brain Funct       Date:  2017-05-04       Impact factor: 3.759

Review 8.  Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

Authors:  Luis A López-Flores; Gloria Pérez-Rubio; Ramcés Falfán-Valencia
Journal:  EXCLI J       Date:  2017-03-06       Impact factor: 4.068

9.  Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.

Authors:  Nada Ezzeldin; Dalia El-Lebedy; Amira Darwish; Ahmed El Bastawisy; Shereen Hamdy Abd Elaziz; Mirhane Mohamed Hassan; Amal Saad-Hussein
Journal:  BMC Cancer       Date:  2018-05-03       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.